Research & Development
Cervical Cancer: Page 3
Cancer tests dominate AMP 2019 | FDA renews warning on biotin interference | Cervical cancer testing at home
Dear LabPulse Member,
November 11, 2019
Older women miss out on cervical cancer screening
Practice guidelines suggest that between the ages of 30 and 65, women should undergo screening with an HPV test every five years or a Pap test every three years in consultation with their doctor.
November 10, 2019
What will it take for home cervical cancer testing to take off?
In a large U.S. study conducted by Kaiser Permanente Washington, women who were overdue for cervical cancer screening were sent home-testing kits for HPV, but only about 12% sent them back. And though the screening rate was improved, the rate of detection for precancerous lesions was not significantly higher. In addition, a sizeable percentage of those with the most worrisome findings failed to follow up with colposcopy as they should have, according to results published November 6 in JAMA Network Open. Nevertheless, researchers have cause for optimism.
November 7, 2019
NeuMoDx adds HPV test with pathology spin-off Self-screen
October 16, 2019
Qiagen liquid biopsy to guide Inovio immunotherapy
The test will be used to help predict which patients will benefit from receiving VGX-3100, a DNA-based immunotherapy in phase III development for the treatment of women positive for HPV types 16 and 18, which cause most cervical cancers and high-grade squamous intraepithelial lesions, the two companies said in a joint statement on May 16. Inovio plans to file a biologics license application (BLA) for the drug in the U.S. in 2021.
May 16, 2019
Page 3 of 3